Forum für Lebensverlängerung
»
Gesundheitsprobleme
»
Erkrankungen, Diagnosen, Therapien
»
Sars-CoV-2 Pandemie
»
Long Covid
Thema drucken
26.10.2025 02:43
Antworten|
#626 |
|
|
Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects |
|
|
Neurological Manifestations of SARS-CoV-2 |
|
|
A Neuroimmunological Axis between systemic autoimmunity and Parkinson's disease following long-COVID: A case series |
|
|
Changes in the Gut Microbiota of Patients After SARS-CoV-2 Infection: What Do We Know? |
|
|
Research Into ME/CFS Pathology Points to Possible Treatments |
|
|
SARS-CoV-2 spike protein causes synaptic dysfunction and p-tau and α-synuclein aggregation leading cognitive impairment: The protective role of metformin |
|
|
Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study |
|
|
T-cell exhaustion in COVID-19: what do we know? |
|
|
ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration? |
|
|
Autonomic dysfunction and vasoregulation in Long COVID-19 are linked to anti-GPCR autoantibodies |
|
|
Autoimmunity in ME/CFS and long COVID: Porto Conference |
|
|
Der Stellenwert von Pregnenolon in der zukünftigen Therapie von ME/CFS und Long-COVID: https://www.dr-med-kristina-schultheiss....-und-long-covid |
|
|
Effect of subcutaneous lidocaine–hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study |
|
|
Long-term N-Acetylcysteine Treatment Accelerates Improvement in Patient-Reported Outcomes for COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled Trial |
|
|
Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction |
|
|
Spike protein–induced VSIR–ISX signaling disrupts metabolic homeostasis and promotes COVID-19–related immune dysfunction |
|
|
Markers of Blood-Brain Barrier Permeability and Immune Exhaustion are Present in Patients with Post-COVID-19 Brain Fog Compared to Controls |
|
|
The Central Role of Macrophages in Long COVID Pathophysiology |
|
|
Brainstem dysfunction as a potential etiology of ME/CFS and long COVID: A mechanical basis |
|
|
Cognition, Cytokines, Blood–Brain Barrier, and Beyond in COVID-19: A Narrative Review |
|
|
REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial |
|
|
Increased phosphorylated tau (pTau-181) is associated with neurological post-acute sequelae of coronavirus disease in essential workers: a prospective cohort study before and after COVID-19 onset |
|
|
Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins |
|
